PE20020917A1 - Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato - Google Patents
Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartatoInfo
- Publication number
- PE20020917A1 PE20020917A1 PE2002000055A PE2002000055A PE20020917A1 PE 20020917 A1 PE20020917 A1 PE 20020917A1 PE 2002000055 A PE2002000055 A PE 2002000055A PE 2002000055 A PE2002000055 A PE 2002000055A PE 20020917 A1 PE20020917 A1 PE 20020917A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- alkyl
- imidazole
- imidazol
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A DERIVADOS DE IMIDAZOL DE FORMULA I DONDE A ES FENILO, PIRIDIN-2-IL, PIRIDIN-3-IL, PIPERIDIN-1-IL; R1 Y R2 SON H, HALOGENO, ALQUILO, CICLOALQUILO, ALQUENILO, TRIFLUOROMETILO, O-TRIFLUOROMETILO, ENTRE OTROS; R3 ES H, ALQUILO, CICLOALQUILO, FENILO, S-ALQUILO, AMINO, ENTRE OTROS; R4 Y R5 SON H, ALQUILO O JUNTO A C FORMAN (CH2)4; R6 Y R6' SON H, ALQUILO; X ES N, C=, Y ES =N, NH, N=CH, CH=; Z ES CR7=, N=, NR7, N=CR7, ENTRE OTROS; R7 ES H, CH2OH, ALQUILO; n ES 0-2; m ES 0-1. SON COMPUESTOS PREFERIDOS 1H-IMIDAZOL, 1-[[1-(4-CLORO-3-METILFENIL)-1H-IMIDAZOL-4-IL]METIL]-2-ETIL; 1H-IMIDAZOL, 1[[1-(4-CLORO-3-METILFENIL)-1H-IMIDAZOL-4-IL]METIL]-2-METIL; 1-(3,4-DICLORO-FENIL)-3-(2-METIL-IMIDAZOL-1-IL-METIL)-1H-PIRAZOL, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON BLOQUEADORES ESPECIFICOS DE UN SUBTIPO DE RECEPTOR DE N-METIL-D-ASPARTATO NMDA Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE NEURODEGENERACION, ENFERMEDAD DE ALZHEIMER, PARKINSON, HUNTINGTON, ESCLEROSIS LATERAL AMIOTROFICA, NEURODEGENERACION ASOCIADA CON INFECCIONES BACTERIANAS VIRICAS, DEPRESION
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01101947 | 2001-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20020917A1 true PE20020917A1 (es) | 2002-10-19 |
Family
ID=8176317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2002000055A PE20020917A1 (es) | 2001-01-29 | 2002-01-24 | Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato |
Country Status (24)
Country | Link |
---|---|
US (3) | US6610723B2 (es) |
EP (1) | EP1358165B1 (es) |
JP (1) | JP4094956B2 (es) |
KR (1) | KR100619106B1 (es) |
CN (2) | CN1489580B (es) |
AR (1) | AR035422A1 (es) |
AT (1) | ATE425147T1 (es) |
BR (1) | BR0206758A (es) |
CA (1) | CA2434813C (es) |
CY (1) | CY1110265T1 (es) |
DE (1) | DE60231477D1 (es) |
DK (1) | DK1358165T3 (es) |
ES (1) | ES2319967T3 (es) |
GC (1) | GC0000318A (es) |
GT (1) | GT200200013A (es) |
HK (2) | HK1063794A1 (es) |
JO (1) | JO2292B1 (es) |
MX (1) | MXPA03006773A (es) |
MY (1) | MY138334A (es) |
PA (1) | PA8537801A1 (es) |
PE (1) | PE20020917A1 (es) |
PT (1) | PT1358165E (es) |
WO (1) | WO2002060877A1 (es) |
ZA (1) | ZA200305626B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003245259A1 (en) * | 2002-05-02 | 2003-11-17 | Neurogen Corporation | Substituted imidazole derivatives: gabaa receptor ligands |
WO2005028467A1 (en) | 2003-09-15 | 2005-03-31 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds |
AU2005258135B2 (en) * | 2004-06-18 | 2011-09-22 | Novartis Vaccines And Diagnostics Inc. | N- (1- (1-benzyl -4-phenyl-1H-imidazol-2-YL) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer |
ITRM20050094A1 (it) * | 2005-03-04 | 2006-09-05 | Univ Siena | Derivati del 1-(1,5-di(4-clorofenil)-2metil-1h-3-pirroli)metil)-4-metilpiperazina (bm 212), procedimento per la loro produzione e uso di essi come antitubercolari. |
US7939556B2 (en) | 2005-10-14 | 2011-05-10 | Neurosearch A/S | Imidazole derivatives and their use for modulating the GABAA receptor complex |
KR100694181B1 (ko) * | 2005-11-25 | 2007-03-12 | 연세대학교 산학협력단 | 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법 |
CA2687973C (en) * | 2007-05-23 | 2015-04-07 | Allergan, Inc. | ((bicylicheteroaryl) imidazolyl)methylheteroaryl compounds as adrenergic receptor agonists |
WO2010009327A1 (en) | 2008-07-17 | 2010-01-21 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compounds for the treatment of pathologies associated with aging and degenerative disorders |
CA2732806A1 (en) | 2008-08-04 | 2010-02-11 | John Wityak | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
KR20120131161A (ko) | 2010-01-25 | 2012-12-04 | 씨에이치디아이 파운데이션, 인코포레이티드 | 특정 키뉴레닌-3-모노옥시게나제 억제제, 그의 제약 조성물 및 사용 방법 |
AU2011217239B2 (en) | 2010-02-18 | 2014-06-12 | B.R.A.I.N. Biotechnology Research And Information Network Ag | Chimeric surface active proteins |
JP2013540145A (ja) * | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤 |
BR112014004741B1 (pt) | 2011-08-30 | 2021-10-13 | Chdi Foundation, Inc | Entidade química, seu uso e composição farmacêutica compreendendo a mesma |
WO2013033068A1 (en) | 2011-08-30 | 2013-03-07 | Stephen Martin Courtney | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
CA2850508A1 (en) * | 2011-09-30 | 2013-04-04 | Endo Pharmaceuticals Inc. | Imidazole derivatives as cyp17 inhibitors for the treatment of cancer |
US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
US8809372B2 (en) | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
MX2017000779A (es) | 2014-07-17 | 2017-07-27 | Chdi Foundation Inc | Metodos y composiciones para el tratamiento de trastornos relacionados con el vih. |
EP3180315B1 (en) * | 2014-08-15 | 2020-03-18 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
DK3180329T3 (da) * | 2014-08-15 | 2020-04-06 | Janssen Pharmaceuticals Inc | Triazoler som nr2b receptorinhibitorer |
MX2018009752A (es) | 2016-02-10 | 2019-02-07 | Janssen Pharmaceutica Nv | 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b. |
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
IL277071B1 (en) | 2018-03-08 | 2024-03-01 | Incyte Corp | Aminopyrizine diol compounds as PI3K–y inhibitors |
WO2019193516A2 (en) | 2018-04-04 | 2019-10-10 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as glun2b receptor modulators |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
JP2022536174A (ja) | 2019-06-14 | 2022-08-12 | ヤンセン ファーマシューティカ エヌ.ベー. | 置換ピラゾロ[4,3-b]ピリジニル及びGLUN2B受容体調節因子としてのそれらの使用 |
AU2020293584A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as GluN2B receptor modulators |
CA3143105A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators |
EP3983072A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Pyrazine carbamates and their use as glun2b receptor modulators |
PE20220386A1 (es) | 2019-06-14 | 2022-03-18 | Janssen Pharmaceutica Nv | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b |
CR20210615A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3627155A1 (de) | 1986-08-11 | 1988-02-18 | Schering Ag | Imidazol-derivate |
CN1040107C (zh) * | 1993-01-02 | 1998-10-07 | 山道士有限公司 | 咪唑基甲基吡啶 |
US5872136A (en) * | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
US5998424A (en) * | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
DE19816880A1 (de) | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
DE60007697T2 (de) | 1999-07-21 | 2004-12-09 | F. Hoffmann-La Roche Ag | Triazolderivate |
-
2001
- 2001-12-20 US US10/029,342 patent/US6610723B2/en not_active Expired - Lifetime
-
2002
- 2002-01-21 KR KR1020037009992A patent/KR100619106B1/ko not_active IP Right Cessation
- 2002-01-21 JP JP2002561027A patent/JP4094956B2/ja not_active Expired - Fee Related
- 2002-01-21 DK DK02714095T patent/DK1358165T3/da active
- 2002-01-21 CA CA002434813A patent/CA2434813C/en not_active Expired - Fee Related
- 2002-01-21 ES ES02714095T patent/ES2319967T3/es not_active Expired - Lifetime
- 2002-01-21 AT AT02714095T patent/ATE425147T1/de active
- 2002-01-21 DE DE60231477T patent/DE60231477D1/de not_active Expired - Lifetime
- 2002-01-21 CN CN028042557A patent/CN1489580B/zh not_active Expired - Fee Related
- 2002-01-21 EP EP02714095A patent/EP1358165B1/en not_active Expired - Lifetime
- 2002-01-21 BR BR0206758-7A patent/BR0206758A/pt not_active IP Right Cessation
- 2002-01-21 CN CN2010101215002A patent/CN101798298B/zh not_active Expired - Fee Related
- 2002-01-21 WO PCT/EP2002/000552 patent/WO2002060877A1/en active IP Right Grant
- 2002-01-21 PT PT02714095T patent/PT1358165E/pt unknown
- 2002-01-21 MX MXPA03006773A patent/MXPA03006773A/es active IP Right Grant
- 2002-01-24 PA PA20028537801A patent/PA8537801A1/es unknown
- 2002-01-24 PE PE2002000055A patent/PE20020917A1/es not_active Application Discontinuation
- 2002-01-25 AR ARP020100261A patent/AR035422A1/es not_active Application Discontinuation
- 2002-01-25 MY MYPI20020294A patent/MY138334A/en unknown
- 2002-01-28 GC GCP20021833 patent/GC0000318A/en active
- 2002-01-28 GT GT200200013A patent/GT200200013A/es unknown
- 2002-01-29 JO JO20029A patent/JO2292B1/en active
-
2003
- 2003-02-11 US US10/364,596 patent/US6683097B2/en not_active Expired - Lifetime
- 2003-02-13 US US10/365,995 patent/US6667335B2/en not_active Expired - Lifetime
- 2003-07-21 ZA ZA200305626A patent/ZA200305626B/en unknown
-
2004
- 2004-09-03 HK HK04106638.1A patent/HK1063794A1/xx not_active IP Right Cessation
-
2009
- 2009-05-15 CY CY20091100522T patent/CY1110265T1/el unknown
-
2011
- 2011-01-26 HK HK11100798.1A patent/HK1146646A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20020917A1 (es) | Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato | |
EA200301213A1 (ru) | Лиганды рецепторов 5-ht и их применение | |
MXPA04006003A (es) | Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano. | |
PE20020506A1 (es) | Derivados de pirazol fusionados como inhibidores de la proteina cinasa | |
HUP0402236A2 (hu) | Heterociklusos vegyületek, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
RS51963B (en) | 4- (2-AMINO-1-HYDROXYETHYL) PHENOL DERIVATIVES AS AGONISTS OF BETA-2 ADRENERGIC RECEPTORS | |
WO2005080384A3 (en) | Benzimidazole derivative and use as aii receptor antagonist | |
ATE390922T1 (de) | 2-aminobenzothiazole als cb1 rezeptor inverse agonisten | |
MA28422B1 (fr) | Derives de n- (1,5-diphenyl-1h-pyrazol-3-yl) sulfonamide avec une affinite pour les recepteurs cb1 | |
RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
EA200700047A1 (ru) | Новые алкильные производные в качестве метаботропных рецепторов глутамата | |
AR036115A1 (es) | Compuesto de n-aroilaminas, composiciones farmaceuticas formuladas con dichos compuestos; uso de los compuestos mencionados en la preparacion de composiciones farmaceuticas para tratar,prevenir enfermedades o trastornos donde se requiere la aplicacion de antagonistas de receptores de la orexina huma | |
MXPA04009784A (es) | Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas. | |
PE20081783A1 (es) | Nuevas 2-aminooxazolinas como ligandos de taar1 | |
JP2013538801A5 (es) | ||
PE20050420A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
KR970706259A (ko) | 도파민 수용체 아류형 특이적 리간드로서 아미노메틸 페닐 이미다졸 유도체(certain aminomethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands) | |
PE20081315A1 (es) | Derivados de benzimidazol como antagonistas de vr-1 | |
CA2383779A1 (en) | N-(indolecarbonyl)piperazine derivatives | |
PE20070355A1 (es) | Antagonistas de cgrp seleccionados y procedimientos para su preparacion | |
PE20041061A1 (es) | Imidazol-4-il-etinil-piridina | |
PE20090592A1 (es) | Nuevos derivados de piperazina-amida | |
ATE306488T1 (de) | Benzimidazol-verbindungen zur verwendung als orl1-rezeptor-antagonisten | |
PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
PE20001084A1 (es) | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |